Table 1.
Patient characteristics at baseline
| All-comers (N = 169) | BM blast-evaluable (n = 95; 56%) | Blast clearance nevaluableb (n = 74; 44%) | |||
|---|---|---|---|---|---|
| BM blast clearance (n = 78) | rwCR/CRh (n = 45)a | Non-response (n = 17) | |||
| Age at diagnosis, years | |||||
| Median (IQR) | 77.0 (72.0-82.0) | 77.0 (71.3-80.0) | 77.0 (70.0-80.0) | 75.0 (71.0-80.0) | 77.5 (73.0-83.8) |
| Min, max | 39.0, 85.0 | 53.0, 85.0 | 53.0, 85.0 | 39.0, 84.0 | 58.0, 85.0 |
| Age at diagnosis (categories), years | |||||
| 18-64 | 14 (8.3) | 6 (7.7) | 5 (11.1) | <4 (<23.5) | 6 (8.1) |
| 65-74 | 49 (29.0) | 24 (30.8) | 13 (28.9) | 6 (35.3) | 19 (25.7) |
| ≥75 | 106 (62.7) | 48 (61.5) | 27 (60.0) | 9 (52.9) | 49 (66.2) |
| Sex | |||||
| Female | 74 (43.8) | 38 (48.7) | 21 (46.7) | 8 (47.1) | 28 (37.8) |
| Male | 95 (56.2) | 40 (51.3) | 24 (53.3) | 9 (52.9) | 46 (62.2) |
| Year of diagnosis | |||||
| 2018 | 31 (18.3) | 17 (21.8) | 11 (24.4) | 4 (23.5) | 10 (13.5) |
| 2019 | 128 (75.7) | 58 (74.4) | 33 (73.3) | 13 (76.5) | 57 (77.0) |
| 2020 | 10 (5.9) | <4 (<5.1) | <4 (<8.9) | 0 (0) | 7 (9.5) |
| AML type | |||||
| De-novo AML | 95 (56.2) | 44 (56.4) | 27 (60.0) | 11 (64.7) | 40 (54.1) |
| s-AML | 74 (43.8) | 34 (43.6) | 18 (40.0) | 6 (35.3) | 34 (45.9) |
| MDS | 59 (34.9) | 26 (33.3) | 15 (33.3) | 6 (35.3) | 27 (36.5) |
| CMML | 8 (4.7) | 5 (6.4) | <4 (<8.9) | 0 (0) | <4 (<5.4) |
| Otherc | 7 (4.1) | <4 (<5.1) | <4 (<8.9) | 0 (0) | <4 (<5.4) |
| Therapy-related AMLd | 14 (8.3) | 7 (9.0) | 4 (8.9) | 4 (23.5) | <4 (<5.4) |
| Practice type | |||||
| Academic | 25 (14.8) | 16 (20.5) | 9 (20.0) | <4 (<23.5) | 6 (8.1) |
| Community | 144 (85.2) | 62 (79.5) | 36 (80.0) | 14 (82.4) | 68 (91.9) |
| Prior malignancy | |||||
| Yes | 52 (30.8) | 23 (29.5) | 14 (31.1) | 11 (64.7) | 18 (24.3) |
| No | 117 (69.2) | 55 (70.5) | 31 (68.9) | 6 (35.3) | 56 (75.7) |
| Blast assessment at diagnosis | |||||
| Yes | 160 (94.7) | 73 (93.6) | 43 (95.6) | 16 (94.1) | 71 (95.9) |
| No | 9 (5.3) | 5 (6.4) | <4 (<8.9) | <4 (<23.5) | <4 (<5.4) |
| BM blast % | |||||
| ≤30 | 66 (39.1) | 27 (34.6) | 12 (26.7) | 7 (41.2) | 32 (43.2) |
| 31-50 | 40 (23.7) | 22 (28.2) | 14 (31.1) | 5 (29.4) | 13 (17.6) |
| >50 | 54 (32.0) | 24 (30.8) | 17 (37.8) | 4 (23.5) | 26 (35.1) |
| Unknown/undocumented | 9 (5.3) | 5 (6.4) | <4 (<8.9) | <4 (<23.5) | <4 (<5.4) |
| Tissue for diagnosis | |||||
| BM | 148 (87.6) | 71 (91.0) | 41 (91.1) | 14 (82.4) | 63 (85.1) |
| PB | 18 (10.7) | 7 (9.0) | 4 (8.9) | 3 (17.6) | 8 (10.8) |
| Unknown/undocumented | <4 (<2.4) | 0 (0) | 0 (0) | 0 (0) | <4 (<5.4) |
| ECOG PS | |||||
| 0 | 32 (18.9) | 15 (19.2) | 6 (13.3) | 4 (23.5) | 13 (17.6) |
| 1 | 68 (40.2) | 33 (42.3) | 21 (46.7) | 6 (35.3) | 29 (39.2) |
| 2 | 33 (19.5) | 14 (17.9) | 10 (22.2) | <4 (<23.5) | 16 (21.6) |
| 3+ | 13 (7.7) | 5 (6.4) | <4 (<8.9) | <4 (<23.5) | 7 (9.5) |
| Missing | 23 (13.6) | 11 (14.1) | 5 (11.1) | <4 (<23.5) | 9 (12.2) |
| ELN 2017 classification | |||||
| Favorable | 22 (13.0) | 13 (16.7) | 8 (17.8) | <4 (<23.5) | 7 (9.5) |
| Intermediate | 37 (21.9) | 18 (23.1) | 11 (24.4) | <4 (<23.5) | 16 (21.6) |
| Adverse | 65 (38.5) | 29 (37.2) | 14 (31.1) | 11 (64.7) | 25 (33.8) |
| Inconclusive | 45 (26.6) | 18 (23.1) | 12 (26.7) | <4 (<23.5) | 26 (35.1) |
All values are n (%) unless otherwise specified. To eliminate the potential to re-identify a patient, any instances where there are fewer than 4 patients have been defined as < 4.
rwCR/CRh is a subset of the 78 patients with BM blast clearance; among all the patients with BM clearance, 13 patients had no cell count data within the ± 14-day time frame. The remaining BM blast-evaluable patients (n = 17) had a non-response.
Patients who did not have evaluable blast clearance due to a lack of BM data found in their records during follow-up.
Including chronic myelogenous leukemia (n = 1), essential thrombocythemia (n = 2), myelofibrosis (n = 1), polycythemia vera (n = 1), and other prior hematologic diseases (n = 2).
Both de-novo AML and s-AML could be therapy-related.
Abbreviations: AML, acute myeloid leukemia; BM, bone marrow; CMML, chronic myelomonocytic leukemia; ECOG PS, Eastern Cooperative Oncology Group performance status; ELN, European LeukemiaNet; IQR, interquartile range; max, maximum; MDS, myelodysplastic syndrome; min, minimum; PB, peripheral blood; rwCR/CRh, real-world complete response/complete response with partial hematologic recovery; s-AML, secondary acute myeloid leukemia.